PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAlfacalcidol
Alfacalcidol
Alfacalcidol is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
aranespBiologic Licensing Application2026-07-07
pulmozymeBiologic Licensing Application2025-12-17
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A11: Vitamins
— A11C: Vitamin a and d, incl. combinations of the two
— A11CC: Vitamin d and analogues
— A11CC03: Alfacalcidol
M: Musculo-skeletal system drugs
— M05: Drugs for treatment of bone diseases
— M05B: Drugs affecting bone structure and mineralization
— M05BB: Bisphosphonates, combinations affecting bone structure and mineralization
— M05BB06: Alendronic acid and alfacalcidol, sequential
HCPCS
No data
Clinical
Clinical Trials
728 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic renal insufficiencyD051436—N1823814835
Vitamin d deficiencyD014808EFO_0003762E55131061534
Secondary hyperparathyroidismD006962EFO_1001173—11614426
HyperparathyroidismD006961EFO_0008506E21.311511422
Healthy volunteers/patients———12—11822
Kidney diseasesD007674EFO_0003086N081165619
NeoplasmsD009369—C807822118
Chronic kidney failureD007676EFO_0003884N18.61356418
HepatitisD006505—K75.91655117
Hepatitis aD006506EFO_0007305B151655117
Show 128 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382—U07.1295—216
InflammationD007249MP_0001845—146—613
Non-small-cell lung carcinomaD002289——7101——12
MelanomaD008545——543—211
Multiple sclerosisD009103EFO_0003885G35261—310
ObesityD009765EFO_0001073E66.91—1—79
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9111—57
CarcinomaD002277—C80.0341—17
LeukemiaD007938—C95142——6
Multiple myelomaD009101—C90.0341——6
Show 105 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175—C34.9058——211
Renal cell carcinomaD002292EFO_0000376—65———9
AdenocarcinomaD000230——46——18
Ulcerative colitisD003093EFO_0000729K51—2——57
Ovarian neoplasmsD010051EFO_0003893C5663———7
Liver neoplasmsD008113EFO_1001513C22.033——27
Small cell lung carcinomaD055752——34———6
Myelodysplastic syndromesD009190—D4625———6
Hepatocellular carcinomaD006528—C22.022——26
Heart failureD006333EFO_0003144I5011——24
Show 153 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Major depressive disorderD003865EFO_0003761F221———34
PsoriasisD011565EFO_0000676L401———23
Premature birthD047928EFO_0003917O601———23
PharmacokineticsD010599——2————2
Non-hodgkin lymphomaD008228—C85.92————2
Biliary tract neoplasmsD001661—C24.92————2
Beta-thalassemiaD017086Orphanet_848D56.11———12
Familial hypophosphatemic ricketsD053098——1———12
Hypophosphatemic ricketsD063730—E83.311———12
Pancreatic ductal carcinomaD021441——1———12
Show 54 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Crohn diseaseD003424EFO_0000384K50————77
Inflammatory bowel diseasesD015212EFO_0003767—————77
Intestinal diseasesD007410—K63.9————66
Sleep initiation and maintenance disordersD007319—F51.01————44
Motor activityD009043EFO_0003940—————44
PregnancyD011247EFO_0002950Z33.1————33
Obstructive lung diseasesD008173——————33
PainD010146EFO_0003843R52————33
Myofascial pain syndromesD009209EFO_1001054—————33
Chronic painD059350——————33
Show 167 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAlfacalcidol
INNalfacalcidol
Description
Alfacalcidol is a member of the class of D3 vitamins that is calciol in which the hydrogen at the 1alpha position is replaced by a hydroxy group. It is an active metabolite of cholecalciferol, which performs important functions in regulation of the calcium balance and the bone metabolism. It has a role as a bone density conservation agent. It is a member of D3 vitamins, a seco-cholestane, a hydroxycalciol and a diol. It is functionally related to a calciol.
Classification
Small molecule
Drug classvitamin D analogs
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O
Identifiers
PDB—
CAS-ID41294-56-8
RxCUI—
ChEMBL IDCHEMBL1601669
ChEBI ID31186
PubChem CID5282181
DrugBankDB01436
UNII IDURQ2517572 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Pulmozyme – Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Aranesp – Amgen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,570 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aranesp
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,529 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use